公司资料
Janux 股价、新闻与催化剂
- 股票代码:
- JANX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
18.60 USD (+6.96%)
收盘价
最后更新: 2026年8月24日
840M USD
市值
股价为何变动
As of Aug 24, 2026, JANX closed up 6.96% at $18.60. No new same-company headline was identified in the current news window.
公司概览
业务概览
Janux Therapeutics is a precision-oncology company developing conditional T-cell engager therapies. Its platform aims to improve tumor targeting while limiting off-tumor toxicity.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Janux sits in specialty oncology biotechnology.
商业模式特征
The company depends on clinical data, platform validation, and the possibility of creating a differentiated immuno-oncology franchise.
生物医药行业定位
Janux is a platform oncology name with meaningful upside if its conditional-engager science continues to validate.
未来催化剂
- Janux's catalysts are PSMA and EGFR T-cell engagers, especially JANX007 and the next clinical updates. The company remains highly event-driven.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。